Newsroom

TOKIO--(BUSINESS WIRE)--TOKIO--(BUSINESS WIRE)--Yokogawa Electric Corporation (TOKIO: 6841, “Yokogawa”), een leider op het gebied van procesautomatiseringstechnologie, kondigt aan dat het een historische mijlpaal heeft bereikt in de implementatie van industriële kunstmatige intelligentie (AI)-oplossingen met Aramco, een van 's werelds toonaangevende geïntegreerde energie- en chemiebedrijven. Yokogawa heeft met succes meerdere autonome AI-agents*1 geïmplementeerd in de Fadhili-gasfabriek van Ara...

TOKYO--(BUSINESS WIRE)--Kirin Holdings Co., Ltd.'s Institute for Future Beverage has successfully developed a fermented ingredient derived from coffee cherries*1. By utilizing coffee cherries*1 —whose pulp and skin are often discarded—as a valuable material, we aim to contribute to the sustainability of coffee farms and reduce environmental impact. Furthermore, due to its ability to enhance body and aroma, this ingredient has shown potential to improve the drinking satisfaction of non-alcoholic...

BANGKOK--(BUSINESS WIRE)--AUTEL has partnered with ZEEKR and Evolt to deliver a high-speed EV charging station “ZEEKR Power @centralwOrld” in Bangkok....

TOKYO--(BUSINESS WIRE)--Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) has begun sales of its i-ED COIL™, a brain aneurysm embolization coil (*1), in Europe as of October. The product obtained EC certification (*2) under an EU Medical Device Regulation (*3) in July and will be distributed primarily in Europe through Kaneka Medical Europe N.V. The i-ED COIL™ provides world-class flexibility, enabled by its specialized wire thickness and structural fea...

大阪（日本）＆ ケンブリッジ（マサチューセッツ州）--(BUSINESS WIRE)--（ビジネスワイヤ） -- 当社は、このたび、原発性IgA腎症を対象とした、疾患修飾作用が期待される抗CD38モノクローナル抗体メザギタマブ（遺伝子組換え）（TAK-079、以下、メザギタマブ）の皮下投与における第１b相、非盲検、プルーフ・オブ・コンセプト臨床試験の新たな中間データを発表しましたので、お知らせします。本試験のデータから、参加者の腎機能（eGFR）は、メザギタマブ最終投与後、最大18カ月間である96週時点まで安定していることが示唆されました１。この結果は、ヒューストンで開催された米国腎臓学会（ＡＳＮ）「Kidney Week 2025」（以下、本学会）で発表されました。 IgA腎症は、10歳から30歳の若年層に多く診断される、生涯にわたって進行する自己免疫疾患であり、腎機能に不可逆的な障害を引き起こします2。IgA腎症の病原性機序に作用する根本的な治療法はなく、既存の治療法では、約5人に1人のIgA腎症患者さんが診断から10年以内に腎不全を発症します3。メザギタマブは、病因に関与するガ...

WASHINGTON--(BUSINESS WIRE)--As President Donald J. Trump prepares to meet Syrian leader Abu Mohammed al-Jolani (also known as Ahmed al-Sharaa) at the White House on Monday, the Foundation for the Development of Western Syria (FDWS) calls on both parties to ensure that this meeting produces tangible commitments that protect Syria’s pluralistic fabric and secure the rights of its vulnerable minorities. For centuries, Syria’s Christian, Alawite, Druze, Kurdish, and other minority communities have...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Company’s Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonstrated that participants receiving a monthly dose of the combination of tobevibart and elebsiran achieved robust and sustained rates of hepatitis delta virus (HDV) RNA target not detected (TND), including those participants with cirrhosis and high baseline HDV RNA. The combination also showed alanin...

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 12, 2025 to file lead plaintiff applications in securities class action lawsuits against V.F. Corporation. (NYSE: VFC), if they purchased or otherwise acquired VFC securities between October 27, 2022 and May 20, 2025, inclusive (the “Class Period”). These actions are pending in the United State...

PHILADELPHIA--(BUSINESS WIRE)--Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at AASLD’s The Liver Meeting®, in Washington DC, that a single intramuscular dose of VRON-0200, its novel, first-in-class, immunotherapy for HBV Functional Cure, induced HBV-specific immune activation, restoration, and HBsAg declines, that were sustained and/or continued up to one-year post dosing, in th...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck’s Enlicitide, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with HeFH in Phase 3 CORALreef HeFH Trial...